On­copep­tides joins up with Vec­tor to com­mer­cial­ize blood can­cer drug Pepax­to in the Mid­dle East, North Africa

About a month af­ter On­copep­tides lost its ap­peal with the FDA to con­tin­ue the ap­proval for Pepax­to in mul­ti­ple myelo­ma pa­tients, the com­pa­ny an­nounced it’s team­ing up with Vec­tor Phar­ma to com­mer­cial­ize the drug in the Mid­dle East and North Africa.

Vec­tor will dis­trib­ute the drug, mar­ket­ed as Pepax­ti out­side of the US, in the re­gion, which in­cludes Sau­di Ara­bia, Qatar, the Unit­ed Arab Emi­rates, Bahrain, Kuwait, Oman, Al­ge­ria, Tunisia, Mo­roc­co, Libya, Lebanon and Iraq. The com­pa­nies are split­ting the rev­enues while Vec­tor will take on all of the costs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER